Literature DB >> 2579631

An antimelanoma monoclonal antibody and the histopathology of uveal melanomas.

R Folberg, L A Donoso, B F Atkinson, C S Ernst, M Herlyn, V V Arbizo.   

Abstract

Monoclonal antibody ME491 identifies a cutaneous melanoma-associated antigen in formaldehyde-fixed, paraffin-embedded tissues. This antibody was applied to tissue sections from 79 cases of formaldehyde-fixed, paraffin-embedded uveal melanomas. Sixty-nine (87.3%) of the 79 cases showed staining by monoclonal antibody ME491, thus demonstrating an antigen shared by cutaneous and uveal melanomas. No relationship between the staining pattern and the patient outcome was detected. Twelve (85.7%) of the 14 cases in which balloon cells were present stained with the antibody. The antibody stained the long posterior ciliary nerve in 12 (38.7%) of 31 cases in which the nerve was present in tissue sections. The antibody cross reacted with the retinal pigment epithelium (16.5% of cases) and a variety of normal nonocular tissues.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2579631     DOI: 10.1001/archopht.1985.01050020127035

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  3 in total

1.  Radioimmunoscintigraphy and immunohistochemistry with melanoma-associated monoclonal antibodies in choroidal melanoma: a comparison of the clinical and immunohistochemical results.

Authors:  D F Schaling; J P van der Pol; M J Jager; M J van Kroonenburgh; J A Oosterhuis; D J Ruiter
Journal:  Br J Ophthalmol       Date:  1990-09       Impact factor: 4.638

2.  Monoclonal antibodies in detection of choroidal melanoma.

Authors:  P J Ringens; R van Haperen; C Vennegoor; P T de Jong; S G van Duinen; D J Ruiter; A W van der Kamp
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

3.  Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes.

Authors:  A M Gown; A M Vogel; D Hoak; F Gough; M A McNutt
Journal:  Am J Pathol       Date:  1986-05       Impact factor: 4.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.